Non-Small Cell Lung Cancer > SHR-1210
~5 spots leftby Apr 2026

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Recruiting in Palo Alto (17 mi)
JY
Overseen byJINGMIN YU, PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Shandong Cancer Hospital and Institute
No Placebo Group
Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is a phase II clinical trial of SHR-1210 （an anti-PD-1 Inhibitor） simultaneously combined with hypofraction radiotherapy in patients with previously treated oligometastatic NSCLC. It is a single center, single arm, open label trial. Subjects with oligometastatic non-small-cell lung cancer who is previously treated will be recruited. 12 subjects will be enrolled at the first part of the study which aims to evaluate the tolerability of SHR-1210 in combination with hypofraction radiotherapy. 30 subjects will be enrolled at the second part of the study which aims to evaluate the primary efficacy and safety of SHR-1210 in combination with hypofraction radiotherapy.

Research Team

JY

JINGMIN YU, PhD

Principal Investigator

Shandong Cancer Hospital and Institute

Eligibility Criteria

Inclusion Criteria

Subjects will voluntarily participate in this study and sign informed consent.
NSCLC subject with 1 to 5 distant metastatic lesions in stage IV.
No clear driven genes (including but not limited to EGFR, ALK).
See 7 more

Treatment Details

Interventions

  • Hypofraction Radiotherapy (Radiation)
  • SHR-1210 (PD-1 Inhibitor)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: SHR-1210 +Hypofraction radiotherapyExperimental Treatment1 Intervention
SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
Loading ...

Who Is Running the Clinical Trial?

Shandong Cancer Hospital and Institute

Lead Sponsor

Trials
125
Patients Recruited
225,000+

Jiangsu HengRui Medicine Co., Ltd.

Industry Sponsor

Trials
663
Patients Recruited
102,000+
Founded
1970
Headquarters
Lianyungang, China
Known For
Oncology Innovations
Top Products
Camrelizumab, Rivoceranib (Apatinib)
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top